rofecoxib has been researched along with Neoplasm Metastasis in 6 studies
Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
| Excerpt | Relevance | Reference |
|---|---|---|
| "com) and infusional 5-fluorouracil (5-FU) as second-line therapy in metastatic colorectal cancer (MCRC)." | 9.11 | Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer. ( Gamucci, T; Gasparini, G; Gattuso, D; Longo, R; Mariani, L; Morabito, A; Sarmiento, R; Torino, F; Vitale, S, 2005) |
| " In preclinical models, there appears to be additive or synergistic effects when combining 5-Fluorouracil (5-FU) with nonsteroidal anti-inflammatory agents (NSAIDs) for the treatment of colorectal neoplasms." | 9.10 | Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study. ( Ashfaq, R; Becerra, CR; Frenkel, EP; Gaynor, RB, 2003) |
| "Previously, we reported that celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, prevented lung metastases but did not affect tumor growth in a model of Ewing sarcoma." | 7.78 | Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma. ( Barlow, M; Edelman, M; Glick, RD; Soffer, SZ; Steinberg, BM, 2012) |
| "com) and infusional 5-fluorouracil (5-FU) as second-line therapy in metastatic colorectal cancer (MCRC)." | 5.11 | Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer. ( Gamucci, T; Gasparini, G; Gattuso, D; Longo, R; Mariani, L; Morabito, A; Sarmiento, R; Torino, F; Vitale, S, 2005) |
| " In preclinical models, there appears to be additive or synergistic effects when combining 5-Fluorouracil (5-FU) with nonsteroidal anti-inflammatory agents (NSAIDs) for the treatment of colorectal neoplasms." | 5.10 | Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study. ( Ashfaq, R; Becerra, CR; Frenkel, EP; Gaynor, RB, 2003) |
| "Previously, we reported that celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, prevented lung metastases but did not affect tumor growth in a model of Ewing sarcoma." | 3.78 | Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma. ( Barlow, M; Edelman, M; Glick, RD; Soffer, SZ; Steinberg, BM, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barlow, M | 1 |
| Edelman, M | 1 |
| Glick, RD | 1 |
| Steinberg, BM | 1 |
| Soffer, SZ | 1 |
| Becerra, CR | 1 |
| Frenkel, EP | 1 |
| Ashfaq, R | 1 |
| Gaynor, RB | 1 |
| Qadri, SS | 1 |
| Wang, JH | 1 |
| Coffey, JC | 1 |
| Alam, M | 1 |
| O'Donnell, A | 1 |
| Aherne, T | 1 |
| Redmond, HP | 1 |
| Gasparini, G | 1 |
| Gattuso, D | 1 |
| Morabito, A | 1 |
| Longo, R | 1 |
| Torino, F | 1 |
| Sarmiento, R | 1 |
| Vitale, S | 1 |
| Gamucci, T | 1 |
| Mariani, L | 1 |
| Grösch, S | 1 |
| Maier, TJ | 1 |
| Schiffmann, S | 1 |
| Geisslinger, G | 1 |
| Dicker, AP | 1 |
| Williams, TL | 1 |
| Grant, DS | 1 |
1 review available for rofecoxib and Neoplasm Metastasis
| Article | Year |
|---|---|
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.
Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Animals; Anti-Inflammatory Agents, N | 2006 |
2 trials available for rofecoxib and Neoplasm Metastasis
| Article | Year |
|---|---|
Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2003 |
Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Flu | 2005 |
3 other studies available for rofecoxib and Neoplasm Metastasis
| Article | Year |
|---|---|
Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma.
Topics: Basement Membrane; Bone Neoplasms; Celecoxib; Cell Line, Tumor; Cell Movement; Cyclooxygenase 2; Cyc | 2012 |
Surgically induced accelerated local and distant tumor growth is significantly attenuated by selective COX-2 inhibition.
Topics: Animals; Cell Division; Cell Line, Tumor; Cyclooxygenase Inhibitors; Lactones; Mice; Mice, Inbred C5 | 2005 |
Targeting angiogenic processes by combination rofecoxib and ionizing radiation.
Topics: Angiogenesis Inhibitors; Animals; Aorta; Apoptosis; Cell Division; Cells, Cultured; Cyclooxygenase 2 | 2001 |